Taysha Gene Therapies (TSHA)
US Market

Taysha Gene Therapies (TSHA) Financial Statements


Taysha Gene Therapies Financial Overview

Taysha Gene Therapies's market cap is currently ―. The company's EPS TTM is $-1.337; its P/E ratio is -2.37; Taysha Gene Therapies is scheduled to report earnings on May 8, 2024, and the estimated EPS forecast is $-0.11. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ 3.60M$ 4.75M$ 2.40M$ 4.70M$ 2.50M
Gross Profit$ 3.60M$ 4.75M$ 2.40M$ 4.70M$ 2.50M
EBIT$ 48.44M$ -115.60M$ -23.15M$ -16.57M$ -55.11M
EBITDA$ 49.08M$ -114.96M$ -22.48M$ -15.97M$ -53.42M
Net Income Common Stockholders$ 47.73M$ -117.07M$ -24.60M$ -17.63M$ -55.70M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 143.90M$ 164.30M$ 45.08M$ 63.42M$ 87.90M
Total Assets$ 172.73M$ 195.77M$ 81.54M$ 101.60M$ 126.28M
Total Debt$ 59.46M$ 57.65M$ 57.88M$ 58.09M$ 58.41M
Net Debt$ -84.44M$ -106.65M$ 12.80M$ -5.34M$ -29.49M
Total Liabilities$ 97.79M$ 244.88M$ 118.60M$ 116.55M$ 125.33M
Stockholders Equity$ 74.94M$ -49.11M$ -37.15M$ -14.95M$ 949.00K
Cash Flow-
Free Cash Flow$ -16.13M$ -17.95M$ -18.69M$ -24.12M$ -88.39M
Operating Cash Flow$ -16.12M$ -17.95M$ -18.74M$ -20.22M$ -88.39M
Investing Cash Flow$ -10.00K$ -3.49M$ 48.00K$ -3.90M$ -24.93M
Financing Cash Flow$ -4.25M$ 140.63M$ 377.00K$ -370.00K$ 52.10M
Currency in USD

Taysha Gene Therapies Earnings and Revenue History

Taysha Gene Therapies Debt to Assets

Taysha Gene Therapies Cash Flow

Taysha Gene Therapies Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis